Music moves - Ettlingen Dementia Study
Phase 2
- Conditions
- F00F01F02F03G31.82G31G30.8Dementia in Alzheimer diseaseVascular dementiaDementia in other diseases classified elsewhere
- Registration Number
- DRKS00023233
- Lead Sponsor
- Deutsche Fernsehlotterie (Deutsches Hilfswerk)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 57
Inclusion Criteria
Residents of Caritas Ettlingen residential care homes (Ettlingen and Rheinstetten) in Baden-Württemberg with a dementia diagnosis
Minimum value of 24 on the Mini-Mental State Exam (MMSE)
Exclusion Criteria
No dementia diagnosis, lower score than 24 on the MMSE, deaf
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method europsychiatric Inventory- Nursing Home (NPI-NH): Behavioural and psychological symptoms of dementia. NPI-NH will be completed three times (1) at the beginning of the study (baseline), (2) at the end of the intervention (after 6 weeks) and (3) 12 weeks after randomization (follow-up).
- Secondary Outcome Measures
Name Time Method Mini-Mental-State Exam (MMSE), Kognitive functioning<br><br>Depression: (Montgomery-Asberg Depression Rating Scale; MADRS)<br><br>Quality of Life - Alzheimer's Disease (QoL-AD)<br><br>Barthel-Index: mobility and daily functioning<br><br>Music Therapy Engagement Scale in Dementia (MTED): Musical, emotional, and verbal Engagement with the music and the therapist<br><br>All questionnaires are completed at three measurement points; (1) at the beginning (baseline), (2) at the end of the intervention after 6 weeks and (3) 12 weeks after randomization.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie music therapy's impact on Alzheimer's disease progression in DRKS00023233?
How does music therapy compare to standard-of-care treatments for vascular dementia in phase II trials?
Are there specific biomarkers that predict response to music-based interventions in unspecified dementia subtypes?
What adverse events are associated with long-term music therapy in degenerative neurological diseases?
What combination approaches with music therapy show promise in treating other degenerative diseases of the nervous system?